Supernus Pharmaceuticals SUPN Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Supernus Pharmaceuticals (SUPN) reported accounts payable and other current liabilities (note 11) of $101.24M in Q1 2026.
- How has Supernus Pharmaceuticals's accounts payable and other current liabilities (note 11) changed year-over-year?
- Supernus Pharmaceuticals's accounts payable and other current liabilities (note 11) increased by 31.7% year-over-year, from $76.89M to $101.24M.
- What is the long-term trend for Supernus Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accounts payable and other current liabilities (note 11) has grown at a 6.4% compound annual growth rate (CAGR), from $78.93M to $107.8M.